Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study

•In this large retrospective multicenter international cohort study including 655 primary treatment refractory or relapsed AML treated with HMAs, only a small subset of patients (5.6%) underwent HSCT after stop of HMA therapy.•Only a minority of patients treated with HMA and subsequent HSCT (6 patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biology of blood and marrow transplantation 2018-08, Vol.24 (8), p.1754-1758
Hauptverfasser: Stahl, Maximilian, DeVeaux, Michelle, Montesinos, Pau, Itzykson, Raphaël, Ritchie, Ellen K., Sekeres, Mikkael A., Majhail, Navneet, Barnard, John, Podoltsev, Nikolai A., Brunner, Andrew M., Komrokji, Rami S., Bhatt, Vijaya R., Al-Kali, Aref, Cluzeau, Thomas, Santini, Valeria, Roboz, Gail J., Fenaux, Pierre, Litzow, Mark, Fathi, Amir T., Perreault, Sarah, Kim, Tae Kon, Prebet, Thomas, Vey, Norbert, Verma, Vivek, Kobbe, Guido, Bergua, Juan, Serrano, Josefina, Gore, Steven D., Zeidan, Amer M.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
AML
Antimetabolites, Antineoplastic - therapeutic use
Female
Graft vs Host Disease - etiology
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cell Transplantation - mortality
Humans
Hypomethylating agents
Leukemia, Myeloid, Acute - therapy
Male
Middle Aged
Retrospective Studies
Salvage Therapy - methods
Salvage Therapy - mortality
Survival
Survival Analysis
Transplant
Transplantation Conditioning - methods
Transplantation Conditioning - mortality
Transplantation, Homologous
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•In this large retrospective multicenter international cohort study including 655 primary treatment refractory or relapsed AML treated with HMAs, only a small subset of patients (5.6%) underwent HSCT after stop of HMA therapy.•Only a minority of patients treated with HMA and subsequent HSCT (6 patients in the entire cohort,
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2018.03.025